Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III Study Testing Nivolumab and Ipilimumab Versus a Carboplatin Based Doublet in First Line Treatment of PS 2 or Elderly (More Than 70 Years Old) Patients With Advanced Non-small Cell Lung Cancer

NCT03351361 is registered in ClinicalTrials.gov with Rennes University Hospital as lead sponsor.

NCT NCT03351361
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03351361 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III Study Testing Nivolumab and Ipilimumab Versus a Carboplatin Based Doublet in First Line Treatment of PS 2 or Elderly (More Than 70 Years Old) Patients With Advanced Non-small Cell Lung Cancer
Lead sponsor
Rennes University Hospital
Phase
Phase 3
Overall status
Completed
Start date
February 19, 2018
Completion date
July 31, 2022
Enrollment
217 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non small cell lung cancer